S&P Futures
3,811.75 -9.50 (-0.25%) Dow Futures
30,936.00 -63.00 (-0.20%) Nasdaq Futures
11,658.00 -33.00 (-0.28%) Russell 2000 Futures
1,717.20 -4.20 (-0.24%) Crude Oil
110.12 +0.34 (+0.31%) Gold
1,818.70 +1.20 (+0.07%)
Actinium Pharmaceuticals, Inc. (ATNM)
After hours:
Chart Events
Performance Outlook
| Previous Close | 5.0300 |
| Open | 5.0500 |
| Bid | 4.8000 x 800 |
| Ask | 4.9800 x 800 |
| Day's Range | 4.8900 - 5.0500 |
| 52 Week Range | 4.4100 - 10.3000 |
| Volume | |
| Avg. Volume | 919,393 |
| Market Cap | 118.209M |
| Beta (5Y Monthly) | 0.32 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.1430 |
| Earnings Date | Jun 29, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 30.67 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for ATNM
Related Research
- Actinium Pharmaceuticals, Inc.Technical Assessment: Bearish in the Intermediate-TermMonday provided a much-needed rest for the stock market after a very large rebound last week. Following that strong week (and we've seen this before during the current decline), the "bottom-callers" are out, but not in big numbers. That's probably a good thing, as others are calling this another bear-market rally. From a technical perspective and using our own interpretation, it is far too early to call the bottom as there is just not enough of the needed evidence.RatingFair ValueEconomic Moat2 days agoArgus Research
- Zacks
Has Alkermes (ALKS) Outpaced Other Medical Stocks This Year?
Here is how Alkermes (ALKS) and Actinium Pharmaceuticals (ATNM) have performed compared to their sector so far this year.
- PR Newswire
Actinium Pharmaceuticals, Inc. Announces 82% of Control Arm Patients Did Not Receive a Bone Marrow Transplant by Conventional Means but 100% of Patients who Received Iomab-B, Including Crossover Patients, in the Phase 3 SIERRA Trial Successfully Engrafted at the Transplantation & Cellular Therapy Tandem Meetings of ASTCT and CIBMTR
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company) a leader in the development of targeted radiotherapies for patients with unmet needs today highlighted data from full patient enrollment in the pivotal Phase 3 SIERRA trial of Iomab-B was presented in an oral presentation at the upcoming Transplantation & Cellular Therapy (TCT) Tandem Meetings of ASTCT and CIBMTR, the combined annual meetings of the American Society for Transplantation and Cellular Therapy (ASTCT) and
- PR Newswire
Actinium Pharmaceuticals, Inc. to Highlight Iomab-B Pivotal Phase 3 SIERRA Trial Data at the Transplantation & Cellular Therapy Tandem Meetings of ASTCT and CIBMTR
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company) a leader in the development of targeted radiotherapies for patients with unmet needs today highlighted its activity at the upcoming Transplantation & Cellular Therapy (TCT) Tandem Meetings of ASTCT and CIBMTR, the combined annual meetings of the American Society for Transplantation and Cellular Therapy (ASTCT) and the Center for International Blood & Marrow Transplant Research (CIBMTR) being held April 23 – 26, 2022 v
